Pharvaris N.V. (PHVS)
NASDAQ: PHVS
· Real-Time Price · USD
24.53
-0.05 (-0.20%)
At close: Sep 26, 2025, 11:03 AM
-0.20% (1D)
| Bid | 24.5 |
| Market Cap | 1.58B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -168.29M |
| EPS (ttm) | -3.65 |
| PE Ratio (ttm) | -6.72 |
| Forward PE | -7.68 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 24.83 |
| Volume | 2,003 |
| Avg. Volume (20D) | 164,366 |
| Open | 24.51 |
| Previous Close | 24.58 |
| Day's Range | 24.51 - 24.84 |
| 52-Week Range | 11.51 - 26.33 |
| Beta | -2.80 |
| Ex-Dividend Date | n/a |
About PHVS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PHVS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PHVS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-9.86%
Pharvaris shares are trading lower after the compa...
Unlock content with
Pro Subscription
2 months ago
-3.02%
Pharvaris shares are trading lower after the company announced a $150 million proposed public offering.
2 months ago · seekingalpha.com
Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient PopulationsPharvaris is advancing deucrictibant, an oral bradykinin B2-receptor antagonist, in two late-stage trials for hereditary angioedema patient populations. Key catalysts include RAPIDe-3 phase 3 topline ...
2 months ago · seekingalpha.com
Pharvaris: More Convenience, More Potency, And More Potential For Future HAE SuccessPharvaris is a late-stage biopharma that specializes in the treatment of hereditary angioedema (HAE). They have only one drug in their pipeline, deucrictibant, of which they are making two oral formul...